Reference : Comment je traite ... une polyarthrite rhumatoïde. L'avènement d'une nouvelle ère thé...
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/72424
Comment je traite ... une polyarthrite rhumatoïde. L'avènement d'une nouvelle ère thérapeutique: les anticorps anti-TNF-alpha
French
[en] How I treat...rheumatoid arthritis. The arrival of a new therapeutic era: anti-tumor necrosis factor alpha antibodies
Kaiser, Marie-Joëlle mailto [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >]
Malaise, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >]
2002
Revue Médicale de Liège
Hopital de Baviere
57
8
486-492
Yes (verified by ORBi)
National
0370-629X
Liège
Belgique
[en] Antirheumatic Agents ; Immunoglobulin G ; Receptors, Tumor Necrosis Factor ; Antibodies, Monoclonal ; Tumor Necrosis Factor-alpha ; infliximab
[en] Rheumatoid arthritis (RA) is the most frequent autoimmune inflammatory
arthropathy. Chronic synovial inflammation usually results in cartilage
destruction, bone erosion and subsequent joint deformities with impaired physical
function. These consequences are more or less delayed by standard
disease-modifying antirheumatic drugs (DMARDs). A better knowledge of the basic
mechanisms of the disease and new biomolecular tools led to the development of
novel biological agents including TNF alpha blockers. TNF alpha is a key
inflammatory cytokine that plays a critically important role in the pathogenesis
of RA. TNF alpha blockers brought dramatic improvements in efficacy of RA
treatment. Here we will review the pathophysiological elements of RA wich explain
the therapeutic efficacy of these TNF alpha blockers and we will describe in
details the molecules, Remicade (Infliximab) and Enbrel (Etanercept), wich will
be very soon used in daily practice in Belgium.
Researchers ; Professionals ; Students ; General public
http://hdl.handle.net/2268/72424
http://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Malaise_2002_RevMedLiege_486-492.pdfPublisher postprint456.33 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.